Boardroom Alpha
Boardroom Alpha
PMN · Additional Proxy Materials (DEFA14A) · Filed April 9, 2026

Promis Neurosciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 9, 2026
Ticker
PMN
Accession
0001104659-26-041485
Boardroom Alpha · Filing insights

PROMIS Neurosciences' board urges voting for all seven director nominees, Baker Tilly as auditor, and stock plan amendment.

About Promis Neurosciences Inc
Market cap
$138M
1Y TSR
−5.4%
3Y TSR
−36.1%
Board grade
C-
Sector
Healthcare
CEO
Neil K Warma
Last annual meeting: May 20, 2026 · View full Promis Neurosciences Inc profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14 (a) of the

Securities Exchange Act of 1934 (Amendment No.  )

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

PROMIS NEUROSCIENCES INC.

(Name of Registrant as Specified in its Charter)

Not applicable.

(Name of Person (s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and 0-11.


GRAPHIC

*Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V92333-P49784 PROMIS NEUROSCIENCES INC. ONE BROADWAY, SUITE 1400 CAMBRIDGE, MA 02142 USA Your Vote Counts! PROMIS NEUROSCIENCES INC. 2026 Annual Meeting Vote by May 19, 2026 11:59 PM ET Vote Virtually at the Meeting* May 20, 2026 10:30 am, Eastern Time Virtually at: www.virtualshareholdermeeting.com/PMN2026 You invested in PROMIS NEUROSCIENCES INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 20, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 6, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

GRAPHIC

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V92334-P49784 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors To elect seven directors, each to serve until the next annual meeting of shareholders and until his or her respective successors is duly elected and qualified, or such director’s earlier death, resignation, or removal. 1a. Eugene Williams For 1b. Neil Cashman, M.D. For 1c. Joshua Mandel-Brehm For 1d. Maggie Shafmaster, Ph.D., J.D. For 1e. Neil K. Warma For 1f. William Wyman For 1g. Slanix Alex, Pharm.D For 2. Appointment of Auditors To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve an amendment to the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Promis Neurosciences Inc (PMN)

Reference

Frequently asked questions

When did Promis Neurosciences Inc file this DEFA14A?
Promis Neurosciences Inc (PMN) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 9, 2026. The accession number assigned by EDGAR is 0001104659-26-041485.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
PROMIS Neurosciences' board urges voting for all seven director nominees, Baker Tilly as auditor, and stock plan amendment. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Promis Neurosciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Promis Neurosciences Inc has filed under CIK 1374339, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer